Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Hepciwel LP
Hepciwel LP (Sofosbuvir & Ledipasvir Tablets) is a potent, fixed-dose combination therapy used in the management of chronic hepatitis C infection caused by the hepatitis C virus (HCV). This combination of Sofosbuvir and Ledipasvir targets different steps of the viral replication cycle, offering a comprehensive approach to eradicate the virus from the body. Hepciwel LP is widely recognized for its efficacy in treating various HCV genotypes, providing patients with a better chance for complete viral clearance and sustained virologic response (SVR).
Uses of Hepciwel LP
Treatment of Chronic Hepatitis C Virus (HCV) Infection
Effective Against Multiple HCV Genotypes
Used in Combination with Ribavirin for Genotype 1 HCV
Used in Genotype 4, 5, and 6 HCV Treatment
Treatment for HIV-HCV Coinfected Patients
Benefits of Hepciwel LP
High Efficacy in Achieving Sustained Virologic Response (SVR)
Well-Tolerated with Minimal Side Effects
Short Treatment Duration (Typically 12 Weeks)
Effective Against Various HCV Genotypes
No Interferon Required
Mechanism of Action of Hepciwel LP
Sofosbuvir: An NS5B polymerase inhibitor that prevents viral RNA replication, thereby halting the production of new virus particles.
Ledipasvir: An NS5A inhibitor that interferes with the HCV replication complex and prevents viral assembly. Together, these two agents block viral replication at multiple stages, leading to complete viral suppression and increased chances of viral eradication.